Abbott Reports Third-Quarter 2023 Results and Raises Midpoin

Sales of $10.1 billion driven by strong underlying base business performance Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior...

Related Keywords

China , Robertb Ford , , Core Laboratory , Cardiovascular Systems Inc , Abxience Holdings , Linkedin , Acelis Connected Health , European Union Medical Device Regulations , European Union , Abbott Laboratories , Facebook , European Union Medical Device , Bigfoot Biomedical , Cardiovascular Systems , Nine Months , Pediatric Nutrition , Adult Nutrition , Rapid Diagnostics , Heart Failure , Emerging Markets , Medical Devices , Diabetes Care , Structural Heart , Freestyle Libre , Aristocrats Index , Investor Relations , Private Securities Litigation Reform Act , Annual Report , Consolidated Statement , Quarter Ended September , Operating Cost , Specified Items , Common Share , Common Shares , Diluted Earnings , Months Ended September , Nine Months Ended September , Medical Device Regulations , Vitro Diagnostics Medical Device Regulations , Medical Device , Vitro Diagnostics Medical Device , Gross Margin , Markets ,